Physical AI News (Japan)

Physical AI, robotics and compute — reported from Japan.

日本語
· Policy & regulation· 日本語で読む

Medtronic’s Hugo Surgical Robot Wins FDA Approval for General Surgery

Medtronic on November 17, 2026, added general surgery to the U.S. indications for its Hugo RAS surgical robot. The procedures include cholecystectomy and appendectomy, representing about 3.5 million surgeries a year in the United States, according to the company. The expanded indication broadens Hugo’s use beyond urology, though actual adoption and usage will need to be assessed separately.

Key facts

  • Medtronic announced on November 17, 2026, that the FDA approved Hugo RAS for use in general surgery.
  • The procedures covered account for about 3.5 million surgeries a year in the United States and, Medtronic says, more than half of the country’s soft-tissue surgeries.
  • Hugo RAS has a modular design that lets users select and position the robotic arms needed for each procedure and patient anatomy.
  • Medtronic forecasts that the cumulative number of Hugo procedures worldwide will exceed 50,000 by the end of its fiscal year.
  • LigaSure RAS Maryland is described as an instrument for use with Hugo RAS that applies vessel-sealing technology used in more than 45 million open and laparoscopic surgeries.

What happened

Medtronic announced on November 17, 2026, that the U.S. Food and Drug Administration approved the Hugo RAS surgical robot for use in general surgery. The procedures covered include cholecystectomy, Roux-en-Y gastric bypass, abdominal wall hernia repair, small bowel resection, inguinal hernia repair and appendectomy. The company says the procedures account for about 3.5 million surgeries a year in the United States.

Why it matters

For U.S. hospitals performing robot-assisted general surgery, Hugo RAS is now an option for procedures beyond urology. Medtronic says the procedures covered account for about 3.5 million operations a year, but the number of procedures eligible for approval does not mean that they will actually shift to robotic surgery. Usage after adoption will be important to track.

Analysis

The regulatory advance expands the range of surgeries that can be performed with Hugo in the United States, from urology to general surgery; it does not involve a redesign of the system or the announcement of a new model. The procedures covered are said to total about 3.5 million a year, but that is Medtronic’s estimate of the number of procedures in scope, not the number that will be performed with Hugo or the number of procedures for which it can be adopted. The breadth of the indication should therefore be distinguished from actual use. On the product side, a key question is how the system’s configuration, which lets users select and position the required arms, fits into operating room design and team workflows for different procedures. The availability of an open console and LigaSure RAS Maryland also affects adoption requirements, including instruments and intraoperative coordination, not just the robot itself. However, the announcement does not provide procedure-specific configurations, adoption costs or comparisons of clinical outcomes with existing methods. Without these details, it is difficult to assess how much the expanded indication will affect hospitals’ equipment choices or procedure volumes. In Medtronic Invests About $700 Million in Cornerstone Robotics, Gains Sales Rights to Sentire Surgical Robot, we covered a partnership to market Sentire in some markets outside the United States. Viewed alongside Hugo’s expanded U.S. indication, the moves show the company expanding the range of procedures for its own system while also marketing another surgical robot in some overseas markets. The announcements do not make clear how the two products are configured or how they will be positioned in the market. In the broader industry, competition will depend not only on the number of procedures in scope, but also on how existing laparoscopic instruments and procedures are used with robotic assistance. Medtronic says general surgery is the fastest-growing area among Hugo procedure types outside the United States and forecasts more than 50,000 procedures worldwide cumulatively by the end of its fiscal year. The company’s materials provide no specific figures for the number of U.S. facilities using the system, general surgery procedures performed, case mix or utilization rates. Usage after the expanded indication and clinical and operational differences compared with existing methods will need to be assessed.

Details

The approval expands Hugo’s indications in the United States through a 510(k) clearance. It covers general surgery procedures throughout the upper abdomen, as well as inguinal hernia repair and appendectomy in the lower abdomen. Medtronic says the procedures account for more than half of all soft-tissue surgeries in the United States. Hugo RAS has a modular design that lets users select the robotic arms needed for each procedure and position them according to the procedure and the patient’s anatomy. The system uses an open console that keeps the surgical team connected with the patient. Medtronic says its LigaSure RAS Maryland, which uses vessel-sealing technology, can also be used with the system. The company says Hugo procedures are growing worldwide at more than twice the rate of the robotic surgery market and forecasts that the cumulative total will exceed 50,000 by the end of its fiscal year.

Sources

Translated from the Japanese original: /news/medtronic-no-shujutsu-shien-robo-hugo-kome-fda-ga-ippan-geka-6f609c. The Japanese version is authoritative if they differ.